down arrow

Galera Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36338D1081
USD
0.03
0 (-1.95%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.020.03

52 Week

0.020.06
Valuation
Technical
Day's Volume

CASH

11.19 k

Shareholding (Mar 2025)

FII

11.86%

Held by 16 FIIs

DII

74.43%

Held by 6 DIIs

Promoter

9.93%

How big is Galera Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Galera Therapeutics, Inc. has a market capitalization of 2.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.16 million for the latest four quarters ending in March 2025. As of December 2024, the company's shareholder's funds were -143.67 million, and total assets amounted to 10.10 million.

Market Cap: As of Jun 18, Galera Therapeutics, Inc. has a market capitalization of 2.12 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, the company reported net sales of 0.00 million and a net profit of -16.16 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds were -143.67 million, and total assets amounted to 10.10 million.

Read More

What does Galera Therapeutics, Inc. do?

22-Jun-2025

Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics to enhance cancer radiotherapy. It has a market cap of $2.12 million and reported a net profit loss of $2 million as of March 2025.

Overview: <BR>Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to transform radiotherapy in cancer, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.12 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: 7.56% <BR>Price to Book: -0.01<BR><BR>Contact Details: <BR>Address: 2 W Liberty Blvd Ste 100, MALVERN PA: 19355-1435 <BR>Tel: 1 610 7251500 <BR>Fax: 1 302 6365454 <BR>Website: https://www.galeratx.com/

Read More

Who are in the management team of Galera Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Galera Therapeutics, Inc. includes Dr. Michael Powell (Independent Chairman), Dr. J. Mel Sorensen (President and CEO), Dr. Emmett Cunningham, and independent directors Mr. Lawrence Alleva, Mr. Kevin Lokay, and Ms. Linda West. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Galera Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Michael Powell, who serves as the Independent Chairman of the Board.<BR>- Dr. J. Mel Sorensen, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Emmett Cunningham, who is a Director.<BR>- Mr. Lawrence Alleva, who is an Independent Director.<BR>- Mr. Kevin Lokay, who is an Independent Director.<BR>- Ms. Linda West, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Galera Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of March 18, 2025, Galera Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages and bearish KST indicators, significantly underperforming the S&P 500 with a 1-year return of -74.84%.

As of 18 March 2025, the technical trend for Galera Therapeutics, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly and monthly MACD readings are mildly bullish. However, the KST is bearish on both weekly and monthly time frames, and there is no trend indicated by Dow Theory or OBV. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple time frames, with a 1-year return of -74.84% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and bearish KST indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

5.45%

stock-summary
Price to Book

-0.01

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
32.63%
0%
32.63%
6 Months
-2.7%
0%
-2.7%
1 Year
-25.0%
0%
-25.0%
2 Years
-82.24%
0%
-82.24%
3 Years
-98.5%
0%
-98.5%
4 Years
-98.02%
0%
-98.02%
5 Years
-99.77%
0%
-99.77%

Galera Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Galera Therapeutics, Inc. technically bullish or bearish?

As of 18 March 2025, the technical trend for Galera Therapeutics, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly and monthly MACD readings are mildly bullish. However, the KST is bearish on both weekly and monthly time frames, and there is no trend indicated by Dow Theory or OBV. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple time frames, with a 1-year return of -74.84% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and bearish KST indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
13.32%
EBIT to Interest (avg)
-8.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
1.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
31.85%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.01
EV to EBIT
-12.67
EV to EBITDA
-12.68
EV to Capital Employed
146.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1153.90%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 7 Schemes (3.78%)

Foreign Institutions

Held by 16 Foreign Institutions (11.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 73.17% vs 80.19% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-4.20",
          "chgp": "73.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.10",
          "val2": "-4.10",
          "chgp": "73.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 67.85% vs 4.98% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-46.70",
          "chgp": "69.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "11.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.60",
          "val2": "-2.30",
          "chgp": "-143.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.00",
          "val2": "-59.10",
          "chgp": "67.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.10
-4.20
73.81%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.10
-4.10
73.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 73.17% vs 80.19% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.10
-46.70
69.81%
Interest
0.00
11.40
-100.00%
Exceptional Items
-5.60
-2.30
-143.48%
Consolidate Net Profit
-19.00
-59.10
67.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 67.85% vs 4.98% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Galera Therapeutics, Inc. stock-summary
stock-summary
Galera Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.
Company Coordinates stock-summary
Company Details
2 W Liberty Blvd Ste 100 , MALVERN PA : 19355-1435
stock-summary
Tel: 1 610 7251500
stock-summary
https://www.galeratx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."